IGHA1 and IgA glomerulonephritis: A preclinical trial on humanized mice demonstrated that FMT modulated IgA nephropathy phenotype and inflammation via increasing serum B cell activation factor (BAFF) and decreasing CD89 cell surface expression, both of which are associated with IgA1 mesangial deposits [179].